203 related articles for article (PubMed ID: 37955580)
1. Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects.
Herzeg A; Borges B; Lianoglou BR; Gonzalez-Velez J; Canepa E; Munar D; Young SP; Bali D; Gelb MH; Chakraborty P; Kishnani PS; Harmatz P; Cohen JL; MacKenzie TC
Prenat Diagn; 2023 Dec; 43(13):1638-1649. PubMed ID: 37955580
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.
Del Grosso A; Parlanti G; Mezzena R; Cecchini M
Adv Drug Deliv Rev; 2022 Sep; 188():114464. PubMed ID: 35878795
[TBL] [Abstract][Full Text] [Related]
3. Advances in therapies for neurological lysosomal storage disorders.
Ellison S; Parker H; Bigger B
J Inherit Metab Dis; 2023 Sep; 46(5):874-905. PubMed ID: 37078180
[TBL] [Abstract][Full Text] [Related]
4. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.
Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC
Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147
[TBL] [Abstract][Full Text] [Related]
5. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
Critchley BJ; Gaspar HB; Benedetti S
Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
[TBL] [Abstract][Full Text] [Related]
7. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
Thomas R; Kermode AR
Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
[TBL] [Abstract][Full Text] [Related]
8. CNS-directed gene therapy for lysosomal storage diseases.
Sands MS; Haskins ME
Acta Paediatr; 2008 Apr; 97(457):22-7. PubMed ID: 18339183
[TBL] [Abstract][Full Text] [Related]
9. Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
Macauley SL
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1(Suppl 1):639-48. PubMed ID: 27491211
[TBL] [Abstract][Full Text] [Related]
10. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies for neuropathic lysosomal storage disorders.
Kelly JM; Bradbury A; Martin DR; Byrne ME
Prog Neurobiol; 2017 May; 152():166-180. PubMed ID: 27725193
[TBL] [Abstract][Full Text] [Related]
12. Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with Mucopolysaccharidosis type VII.
Nguyen QH; Witt RG; Wang B; Eikani C; Shea J; Smith LK; Boyle G; Cadaoas J; Sper R; MacKenzie JD; Villeda S; MacKenzie TC
Sci Transl Med; 2020 Feb; 12(532):. PubMed ID: 32102934
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lysosomal storage diseases: recent patents and future strategies.
Ortolano S; Viéitez I; Navarro C; Spuch C
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
[TBL] [Abstract][Full Text] [Related]
14. Oral small molecule therapy for lysosomal storage diseases.
Weinreb NJ
Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
[TBL] [Abstract][Full Text] [Related]
15. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
[TBL] [Abstract][Full Text] [Related]
16. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
Li M
Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.
Simonis H; Yaghootfam C; Sylvester M; Gieselmann V; Matzner U
Hum Mol Genet; 2019 Jun; 28(11):1810-1821. PubMed ID: 30657900
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy approaches for lysosomal storage disease: next-generation treatment.
Byrne BJ; Falk DJ; Clément N; Mah CS
Hum Gene Ther; 2012 Aug; 23(8):808-15. PubMed ID: 22794786
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for lysosomal storage diseases (LSDs) in large animal models.
Haskins M
ILAR J; 2009; 50(2):112-21. PubMed ID: 19293456
[TBL] [Abstract][Full Text] [Related]
20. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
Solomon M; Muro S
Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
